Volume 4, Issue 12: What does CFTR tell us about Lung Disease? -PODCAST
e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 4, Issue 12)
Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.
After participating in this activity, the participant will demonstrate the ability to:
- Recognize that ivacaftor is a new therapy for CF patients specifically with the mutation G551D that it has been shown to correct the CFTR protein, and result in improved lung function.
- Describe how CFTR genotype influences lung function, and factors accounting for variability in lung function even among individuals with the same genotype.
- Describe the use of CFTR genotype to facilitate making diagnoses of CF, predicting prognoses, and selecting therapies.
Patrick Sosnay, MD
Assistant Professor of Medicine
Division of Pulmonary & Critical Care Medicine,
McKusick-Nathans Institute for Genetic Medicine
Johns Hopkins Cystic Fibrosis Center
The Johns Hopkins University
- 0.50 ANCC